Protective antiviral shield against lymphoma threat.

Hepatitis B Virus Reactivation: Is Your DLBCL Treatment Safe?

Reese Marlowe monogram
Reese Marlowe in Health & Wellness October 2026 • 4 min read.

"A comprehensive guide to understanding and mitigating HBV reactivation risks in advanced-stage DLBCL patients undergoing chemotherapy."


Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that requires intensive treatment, often involving chemotherapy regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). While these treatments are effective at targeting cancer cells, they can also weaken the immune system, creating opportunities for opportunistic infections and the reactivation of dormant viruses, particularly the hepatitis B virus (HBV).

Hepatitis B virus reactivation occurs when the virus, previously under control, starts replicating again, leading to liver inflammation and potential liver damage. For patients with DLBCL who are also HBV carriers, this reactivation can complicate cancer treatment, leading to interruptions, reduced chemotherapy doses, and poorer overall outcomes. Understanding the risk factors, preventative strategies, and management approaches for HBV reactivation is crucial for ensuring safer and more effective cancer treatment.

This article explores the critical aspects of HBV reactivation in DLBCL patients, focusing on how antiviral prophylaxis, particularly with drugs like tenofovir and lamivudine, can mitigate these risks. We will examine recent research, clinical guidelines, and practical steps patients and healthcare providers can take to protect against HBV reactivation, allowing for uninterrupted and successful cancer therapy.

AI Search Multiple angles on this topic

HBV Reactivation Risk in DLBCL

Patients with past hepatitis B virus (HBV) infection who receive anticancer therapies associated with high reactivation risk, including anti-CD20 monoclonal antibodies or stem-cell transplantation, should receive antiviral prophylaxis during treatment and for at least 12 months afterward. DLBCL patients with resolved hepatitis B have a higher risk of HBV reactivation after R-CHOP chemotherapy than patients who are HBsAg-negative and HBcAb-negative. However, data on HBV-related versus non-HBV-related DLBCL and on reactivation risk factors after R-CHOP remain limited.

The Evidence Base Emerges

A clinical review examined 278 patients with DLBCL treated with rituximab-containing therapy at Sun Yat-sen University Cancer Center in China between January 2004 and May 2008. The study evaluated predictive factors for HBV reactivation, hepatitis development, and survival using univariate and multivariate analyses. Later research summarized the epidemiology, pathogenesis, clinical characteristics, HBV reactivation, and antiviral therapies associated with HBV-associated DLBCL. HBV-associated DLBCL has been reported to have unique clinical characteristics, poorer treatment effects, and inferior prognosis.

Understanding HBV Reactivation in DLBCL Patients

Protective antiviral shield against lymphoma threat.

Hepatitis B virus reactivation is a significant concern for patients with DLBCL undergoing chemotherapy. The use of immunosuppressive agents, especially rituximab (an anti-CD20 monoclonal antibody), can increase the risk of HBV reactivation. Rituximab targets B cells, which are crucial for controlling viral infections, thereby weakening the body’s ability to suppress HBV. The risk is particularly elevated in patients who are hepatitis B surface antigen (HBsAg) positive, indicating an active or chronic HBV infection.

Several factors contribute to the likelihood of HBV reactivation: Type of Chemotherapy Regimen: R-CHOP and similar regimens are highly effective against DLBCL but also significantly suppress the immune system. HBV Status: Patients who are HBsAg positive are at the highest risk, but even those with resolved HBV infections (HBsAg negative, but hepatitis B core antibody [HBcAb] positive) can experience reactivation. IPI Score: Patients with higher International Prognostic Index (IPI) scores, indicating more aggressive disease, are also at greater risk of antiviral prophylaxis failure.

Type of Chemotherapy Regimen: R-CHOP and similar regimens are highly effective against DLBCL but also significantly suppress the immune system. HBV Status: Patients who are HBsAg positive are at the highest risk, but even those with resolved HBV infections (HBsAg negative, but hepatitis B core antibody [HBcAb] positive) can experience reactivation. IPI Score: Patients with higher International Prognostic Index (IPI) scores, indicating more aggressive disease, are also at greater risk of antiviral prophylaxis failure.
AI Search Multiple angles on this topic

Limits of Reactivation Estimates

A study of prophylactic antiviral therapy defined HBV-reactivation-related hepatitis as hepatitis accompanied by an elevation in serum HBV DNA. The authors noted that not all HBsAg-positive patients underwent routine serum HBV DNA monitoring. Consequently, this definition might have underestimated the incidence of HBV-reactivation-related hepatitis. The reported incidence was nevertheless similar to that in previous studies.

Resolved Infection Still Matters

HBV reactivation has been reported in patients with B-cell lymphoma who have resolved hepatitis B. These patients are HBsAg-negative but HBcAb-positive, indicating that the absence of detectable surface antigen does not eliminate reactivation concerns. A study specifically assessed HBV reactivation in this patient population.

Early detection and preventative measures are critical in managing HBV reactivation. Routine screening for HBV markers (HBsAg, HBcAb) should be performed before initiating chemotherapy. Patients identified as HBV carriers or with resolved HBV infection should receive antiviral prophylaxis to prevent reactivation.

Future Directions and the Importance of Continued Research

While current strategies are effective, ongoing research is essential to refine and improve HBV reactivation prevention and management in DLBCL patients. Larger studies are needed to demonstrate the survival advantages of using tenofovir as a prophylactic agent, particularly in patients with advanced-stage DLBCL and adverse IPI scores. Additionally, investigating the cost-effectiveness of different antiviral strategies will help optimize resource allocation and improve patient outcomes. By staying informed and proactive, healthcare providers and patients can work together to ensure safer, more effective lymphoma treatment.

AI Search Multiple angles on this topic

Clarifying HBV-Associated DLBCL

Advanced studies have identified a biological correlation between HBV and B-cell lymphoma, particularly DLBCL. Patients with HBV-associated DLBCL are characterized clinically by advanced disease stage, poor response to front-line immunochemotherapy regimens, and worse outcomes. Future research must continue examining the biological relationship between HBV and DLBCL and its implications for treatment.

Reactivation Can Be Delayed

The World Health Organization estimated that 296 million people were chronic HBV carriers worldwide in 2019, with 1.5 million new infections each year. Chemotherapy or immunosuppressive therapy can cause HBV reactivation in people with current or previous HBV infection. A reported patient experienced HBV reactivation 13 years after completing rituximab-containing chemotherapy and later developed DLBCL after hepatitis B had improved. The case highlights that clinically important reactivation may occur long after treatment has ended.

HBV reactivation rates against their comparison groups

  • 2.4% vs 17.9% patientsDuring mean follow-up of 18 months, HBV reactivation occurred in 2.4% of patients receiving entecavir prophylaxis and 17.9% of controls.[1]
  • 22.9% vs 59.1% patientsIn a retrospective analysis of HBsAg-positive patients, reactivation was reported in 22.9% of those receiving prophylaxis and 59.1% of those not receiving it.[2]
  • 6.3% vs 39.3% patientsThe cross-sectional analysis reported reactivation rates of 6.3% with entecavir and 39.3% with lamivudine prophylaxis.[2]

What the comparisons suggest-and cannot settle

Across the reported comparisons, prophylaxis groups had lower observed reactivation rates than their respective comparison groups. These figures come from different analyses and populations, so they do not establish that the size of the difference would be the same in every setting.[1] [2]

The higher hepatitis incidence in HBsAg-positive than HBsAg-negative patients identifies a difference between those groups, but does not by itself explain why the difference occurred or establish an individual patient's outcome.[3]

How the evidence differs across treatment comparisons

Among patients with resolved hepatitis B treated with R-CHOP, five of 21 developed reactivation, and one of those patients died of hepatic failure. This comparison was reported with P = 0.0148, but the excerpt does not specify the comparator behind that P value.[4]

A separate analysis found no statistically significant difference in cumulative reactivation incidence between its groups in either the intention-to-treat or per-protocol analysis.[5]

The evidence also records hepatitis arising early after R-CHOP-like chemotherapy in specified patients who had no antiviral prophylaxis or received lamivudine prophylaxis. This describes timing in those cases, rather than establishing how often early hepatitis occurs across all treated patients.[3]

What evidence could clarify prevention and monitoring

  • How might the apparent relationship between prophylaxis and reactivation change after accounting for differences between patients? A meta-analysis subgroup analysis did not support an association, and adjustment for detectable anti-HBs antibodies also did not produce a significant association.[6]

Common questions about HBV reactivation

Can HBV reactivation lead to severe illness?

It can sometimes result in fulminant hepatitis, hepatic failure, or death in patients treated with CD20-directed cytolytic antibodies, including rituximab.[7]

Sources

  1. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. (pubmed.ncbi.nlm.nih.gov)
  2. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. (pubmed.ncbi.nlm.nih.gov)
  3. Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy (pmc.ncbi.nlm.nih.gov)
  4. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. (pubmed.ncbi.nlm.nih.gov)
  5. Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study. (pubmed.ncbi.nlm.nih.gov)
  6. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. (pubmed.ncbi.nlm.nih.gov)
  7. DailyMed - RITUXAN- rituximab injection, solution (dailymed.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What does Hepatitis B virus reactivation mean, and why is it a concern during DLBCL treatment?

Hepatitis B virus reactivation refers to the re-emergence of active Hepatitis B Virus (HBV) replication in individuals who were previously under control, often due to a weakened immune system. This is significant because, in the context of Diffuse Large B-Cell Lymphoma (DLBCL) treatment, particularly with chemotherapy regimens like R-CHOP, the immunosuppressive effects can trigger HBV reactivation, leading to liver inflammation, liver damage, and potentially interrupting or reducing the effectiveness of cancer treatment. The implications include the need for careful monitoring and preventative antiviral strategies to protect vulnerable patients.

2

What is R-CHOP, and why does it matter in the context of Hepatitis B Virus?

The R-CHOP regimen is a chemotherapy treatment that includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. It is important because it is a standard and highly effective treatment for Diffuse Large B-Cell Lymphoma (DLBCL). However, it also carries risks, notably weakening the immune system and increasing the likelihood of Hepatitis B Virus (HBV) reactivation. The implications are that while R-CHOP targets cancer cells effectively, precautions must be taken, such as antiviral prophylaxis, especially in patients who are HBV carriers or have resolved HBV infections, to mitigate the risk of HBV reactivation and ensure uninterrupted cancer therapy.

3

What is Tenofovir, and why is it used for patients undergoing DLBCL treatment?

Tenofovir is an antiviral medication used as a prophylactic agent to prevent Hepatitis B Virus (HBV) reactivation in individuals undergoing immunosuppressive therapies, like chemotherapy for Diffuse Large B-Cell Lymphoma (DLBCL). It is important because it helps suppress HBV replication, reducing the risk of liver inflammation and damage. Using Tenofovir allows patients to continue their cancer treatment without interruption and ensures better overall outcomes. However, research continues to determine the most cost-effective strategies for using antiviral medications, particularly for patients with advanced-stage DLBCL.

4

What does it mean if I am hepatitis B surface antigen (HBsAg) positive?

The hepatitis B surface antigen (HBsAg) test detects the presence of the hepatitis B virus on the surface of the liver cells. It is important because it indicates either an active or chronic Hepatitis B Virus (HBV) infection. For patients with Diffuse Large B-Cell Lymphoma (DLBCL) undergoing chemotherapy, being HBsAg positive significantly elevates the risk of HBV reactivation. The implications are that patients who test positive for HBsAg should receive antiviral prophylaxis to prevent HBV reactivation and ensure the safe and effective completion of their cancer treatment. Another important marker is hepatitis B core antibody (HBcAb), where being positive indicates resolved HBV infections, where these patients can also experience reactivation.

5

What is the International Prognostic Index (IPI) score, and how does it relate to Hepatitis B Virus reactivation?

The International Prognostic Index (IPI) score is a tool used to assess the aggressiveness and prognosis of Diffuse Large B-Cell Lymphoma (DLBCL). It is important because patients with higher IPI scores, indicating more aggressive disease, are at greater risk of antiviral prophylaxis failure during chemotherapy. The implications are that healthcare providers need to be particularly vigilant in monitoring these patients for Hepatitis B Virus (HBV) reactivation, and potentially consider more aggressive preventative strategies to ensure the best possible outcomes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.